Overview of Percocet 7.5/325
| Property | Description |
|---|---|
| Active Ingredients | Oxycodone Hydrochloride, Acetaminophen |
| Form | Fixed-Dose Combination Tablet (Oral) |
| Pharmacological Class | Opioid and Non-Opioid Analgesic Combination |
| General Purpose | Analgesia for moderate to severe pain |
| Origin | Semisynthetic (Oxycodone) and Synthetic (Acetaminophen) |
What is Percocet 7.5/325: A Definition and Classification
Percocet 7.5/325 is a prescription-only medication provided as an immediate-release tablet, classified as a narcotic analgesic combination. This fixed-dose combination (FDC) is structurally distinct from single-agent formulations and is utilized for the management of pain.
The medicine's identity is established by the presence of a semisynthetic opioid analgesic, Oxycodone Hydrochloride, alongside the non-opioid analgesic and antipyretic, Acetaminophen (or Paracetamol). This combined formulation is clinically recognized for its effectiveness in the management of pain that requires the potency of an opioid component.
Composition and Dual-Action Pharmacological Group
The specific designation 7.5/325 is critical, representing the precise quantity of active ingredients in each tablet: 7.5 milligrams (mg) of Oxycodone Hydrochloride and 325 milligrams (mg) of Acetaminophen. This dual composition confers two distinct modes of action to the medicine.
The formulation functions as an opioid agonist and an antipyretic, ensuring the medicine targets pain through complementary routes simultaneously. Pharmacological studies support that combining an opioid with Acetaminophen yields a therapeutic advantage over using the opioid alone. This strategic combination is its primary differentiating factor within the analgesic market.
General Therapeutic Purpose and Function
The general therapeutic purpose of this FDC tablet is the analgesia of moderate to severe pain, which typically requires more than non-opioid options can provide. The medicine works by leveraging the synergistic effects of its two components: the opioid acts centrally to block pain signals, and the non-opioid modifies pain perception while contributing to temperature reduction.
This integrated function offers robust pain relief suitable for various situations, such as post-operative discomfort or injury-related pain. The auxiliary benefit of fever reduction where pain is accompanied by elevated body temperature further underscores the utility of the dual-compound approach.
Regulatory References

